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• Infants in both groups had similar baseline 
characteristics. There was no difference in most 
outcome variables.  
• However, we did find significantly fewer infants in the 
fosphenytoin group vs phenobarbital group with 
moderate to severe neurodevelopmental delay at 18-
month assessments. 
Fosphenytoin as well as phenobarbital are equally 
efficacious as first-line AED in neonatal seizure control 
but neonates treated with fosphenytoin have significantly 
better neurodevelopmental outcomes at 18 months of 
age.  
A single center retrospective cohort review of all 
neonates admitted to a Level III NICU during the study 
period with clinical and electroencephalographic (EEG) 
diagnosis of seizures.  The primary outcome variable 
was long-term neurodevelopmental status at 18 months 
of age 
• Neonatal seizures are common in both term and preterm 
infants, often indicative of an underlying pathological 
process and associated with high morbidity and 
mortality.  
• While neurodevelopmental outcome is strongly 
influenced by etiology, uncontrolled seizures themselves 
can exacerbate brain injury. 
• The question of which therapy to initiate as first line is 
highly disputed, as some Anti-epileptic drugs (AEDs) 
may themselves have negative impact on the developing 
brain. 
  
OBJECTIVE:  To compare the efficacy of fosphenytoin and phenobarbital as 
first-line anti-epileptic drug (AED) for neonatal seizures treatment and to 
assess neurodevelopmental outcomes at 18 months of age.  
 
METHODS: A single center retrospective cohort review of all neonates 
admitted to a Level III NICU during the study period with clinical and 
electroencephalographic (EEG) diagnosis of seizures. Data collection 
included maternal antenatal complications as well as neonatal baseline 
characteristics and clinical outcomes, including details pertaining to seizure 
diagnosis and management. The primary outcome variable was long-term 
neurodevelopmental status determination by a pediatric neurologist and/or 
developmental-behavioral specialist at 18 months of age.   
 
RESULTS:  Infants in both groups had similar baseline characteristics for 
neonatal variables (gestational age, birth weight, gender, mode of delivery 
and 5-minute APGAR score) as well as maternal antenatal complications. 
For outcome variables there was no difference in EEG/neuroimaging 
findings, time to seizure control, recurrence of seizures, need for a second-
line AED, and discharge home on AED. However, we did find significantly 
fewer infants in the fosphenytoin group vs phenobarbital group (4.8% vs 
30%, p=0.02) with moderate to severe neurodevelopmental delay at 18-
month assessments.  
 
CONCLUSIONS: Fosphenytoin as well as phenobarbital are equally 
efficacious as first-line AED in neonatal seizure control but neonates treated 
with fosphenytoin have significantly better neurodevelopmental outcomes at 
18 months of age. Further multicenter studies are recommended to confirm 
our findings.  
Abstract 
References 
     Methods  
Introduction 
Results 
Conclusions 
Figures/Graphs 
• OBJECTIVE: To compare the efficacy of fosphenytoin 
and phenobarbital as first-line anti-epileptic drug 
(AED) for neonatal seizures treatment and to assess 
neurodevelopmental outcomes at 18 months of age.  
• METHODS 
• RESULTS 
• CONCULSIONS 
 
Introduction 
Click headings to further view content 
Efficacy of Fosphenytoin as First-line Anti-epileptic for Neonatal Seizures as Compared to Phenobarbital  
  
Veronica Alix MD1, Mansi James DO1, Anthony Jackson MD1,2, Paul Visintainer PhD3, Rachana Singh MD MS1  
1Department of Pediatrics, UMMS-Baystate, Springfield, MA, 2Department of Neurology, UMMS-Baystate, Springfield, MA, 
3Epidemiology & Biostatistics, Office of Research, UMMS-Baystate, Springfield, MA  
• Clinical Characteristics for First line Anti-Epileptic Drugs 
• Outcome Variables for First line Anti-Epileptic Drugs 
• Comparative effectiveness of Fosphenytoin and 
phenobarbital 
• 18 Month Neurological Outcome 
 
  
• Infants in both groups had similar baseline 
characteristics. There was no difference in most 
outcome variables.  
• However, we did find significantly fewer infants in the 
fosphenytoin group vs phenobarbital group with 
moderate to severe neurodevelopmental delay at 18-
month assessments. 
Fosphenytoin as well as phenobarbital are equally 
efficacious as first-line AED in neonatal seizure control 
but neonates treated with fosphenytoin have significantly 
better neurodevelopmental outcomes at 18 months of 
age.  
A single center retrospective cohort review of all 
neonates admitted to a Level III NICU during the study 
period with clinical and electroencephalographic (EEG) 
diagnosis of seizures.  The primary outcome variable 
was long-term neurodevelopmental status at 18 months 
of age 
• Neonatal seizures are common in both term and preterm 
infants, often indicative of an underlying pathological 
process and associated with high morbidity and 
mortality.  
• While neurodevelopmental outcome is strongly 
influenced by etiology, uncontrolled seizures themselves 
can exacerbate brain injury. 
• The question of which therapy to initiate as first line is 
highly disputed, as some Anti-epileptic drugs (AEDs) 
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Neonatal seizures are common in both term and preterm infants, 
ranging with a risk of seizures being highest in the neonatal period 
(1.8 to 3.5/1000 live births in the United States). They are often 
indicative of an underlying pathological process such as hypoxic 
ischemic encephalopathy, intracranial hemorrhage, stroke or sepsis. 
Neonatal seizures are associated with high morbidity and mortality. 
While outcome is strongly influenced by etiology, there is evidence 
that uncontrolled seizures can exacerbate brain injury and have a 
negative impact on neurodevelopment.  The question of which 
therapy to initiate is highly disputed, as some AEDs may have 
negative effects on the developing brain. 
Currently the most commonly used first line treatment in new 
onset neonatal seizures is phenobarbital in most clinical settings, 
despite known negative impact on the developing neonatal brain. 
Phenobarbital binds to the GABA receptor, improving the effect of 
GABA by extending the duration of chloride channel openings and 
allows increased flow of chloride ions across the membrane.  This 
causes neuronal hyperpolarization and is in fact excitatory in nature 
in neonates.  When neuronal activity is abnormally suppressed, the 
timing and sequence of synaptic connections can be disrupted and 
it causes nerve cells to receive signals to self- destruct resulting in 
apoptosis.  Fosphenytoin, a phosphate ester prodrug,  is equally 
efficacious with no known neurocognitive side effects, though 
cardiac side effects are well known.  
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A single center retrospective cohort review of all 
neonates admitted to a Level III NICU during the study 
period with clinical and electroencephalographic (EEG) 
diagnosis of seizures. Data collection included maternal 
antenatal complications as well as neonatal baseline 
characteristics and clinical outcomes, including details 
pertaining to seizure diagnosis and management. The 
primary outcome variable was long-term 
neurodevelopmental status determination by a pediatric 
neurologist and/or developmental-behavioral specialist 
at 18 months of age.   
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• Infants in both groups had similar baseline 
characteristics for neonatal variables (gestational 
age, birth weight, gender, mode of delivery and 5-
minute APGAR score) as well as maternal antenatal 
complications as shown in Table 1.  
 
• For outcome variables there was no difference in 
EEG, neuroimaging findings, recurrence of seizures, 
need for a second-line AED, time to seizure control 
and discharge home on AED as shown in Table 2 
and Figure 1.  
 
• However, we did find significantly fewer infants in the 
fosphenytoin group vs phenobarbital group (4.8% vs 
30%, p=0.02) with moderate to severe 
neurodevelopmental delay at 18-month assessments 
as demonstrated in Figure 2.  
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Variable Level Fosphenytoin 
Total N = 23 
N (%) 
Phenobarbital 
Total  N = 80 
N (%) 
P-value 
Gestational Age, weeks 
(Mean, SD) 
38.4 (± 2.3) 38.8 (± 2.7) 
 
0.57 
Gender Male 9 (39.1) 47 (58.8) 0.10 
Birth weight, grams 
(Mean, SD) 
3144.3 (630.6)  3298.5 (631.6) 0.31 
Antenatal Complication Maternal Abruption 
Maternal Uterine Rupture 
Maternal Chorioamnionitis 
Fetal Cord Prolapse 
Fetal Shoulder Dystocia 
Other 
1 (8.3) 
0 (0) 
1 (8.3) 
0 (0) 
0 (0) 
10 (83.3) 
4 (7) 
1 (1.8) 
10 (17.5) 
1 (1.8) 
1 (1.8) 
40 (70.2) 
0.92 
Mode of Delivery C-section 9  (39.1) 38 (47.5) 0.64 
5 – minute APGAR score 
median (IQR)  
9.0 (3.0, 9.0)  8.0 (5.0, 9.0)  0.76 
Clinical Diagnosis HIE 
IVH 
Infarct 
Hemorrhage 
Hypoglycemia 
Sepsis 
Drug Withdrawal Syndrome 
Other (Metabolic, Genetic) 
9 (40.9) 
0 (0) 
3 ( 13.6) 
2 ( 9.1) 
1 (4.5) 
1 ( 4.5) 
1 (4.5) 
5 ( 22.7) 
28 ( 38.4) 
1 ( 1.4) 
10 ( 13.7) 
9 ( 12.3) 
1 ( 1.4) 
1 ( 1.4) 
2 ( 2.7) 
21 ( 28.8) 
0.82 
0%
10%
20%
30%
40%
50%
60%
Recurrent Seizures
P-value 0.80
Need for 2nd AED
P-value 1.00
Discharge Home
on AED
P-value 1.00
Fosphenytoin
Phenobarbital
 Variable Level Fosphenytoin 
Total N = 23 
N (%) 
Phenobarbital 
Total  N = 80 
N (%) 
P-value 
aEEG Yes 21 (95.5) 47 (61) 0.001 
Full complement EEG Yes 21 (100) 75 (96.2) 1.00 
EEG Seizure Focus ( Side) Right  
Left 
Bilateral 
7 (46.7) 
5 (33.3) 
3 (20) 
12 (26.7) 
22 ( 48.9) 
11 (24.4) 
0.35 
EEG Seizure Focus ( Site) Frontal  
Temporal 
Occipital 
Multifocal 
1 (9.1) 
8 (72.7) 
0 (0) 
2 (18.2) 
6 (15.8) 
22 (57.9) 
4 (10.5) 
6 (15.8) 
0.76 
Head US IVH 
Infarct 
Other 
0 (0) 
1 (33.3) 
2 (66.7) 
6 (13.6) 
1 (2.3) 
37 (84.1) 
0.16 
MRI Prior to discharge HIE 
IVH 
Infarct 
Other 
4 (25.0) 
1 (6.3) 
5 (31.3) 
6 (37.5) 
20 ( 31.3) 
9 (14.1) 
14 (21.9) 
21 (32.8) 
0.77 
MRI Post Discharge HIE 
Infarct 
Resolved 
Other 
1 (16.7) 
0 (0) 
3 (50) 
2 (33.3) 
2 (4.5) 
4 (9.1) 
10 (22.7) 
28 ( 63.6) 
0.18 
Time to seizure control (Hours) 
(Median, IQR) 
1 (0, 16) 1 (0, 13) 0.97 
Fosphenytoin Phenobarbital 
Normal to Mild Delay
Moderate to Severe
Delay
Figure 2.  At neurodevelopmental or neurology follow ups at 18 
months, 30% of infants treated with phenobarbital had a moderate to 
severe delay while 5% of infants treated with fosphenytoin had a 
moderate to severe developmental delay 
Table 2. There was no difference in EEG, neuroimaging findings, 
recurrence of seizures, or time to seizure control.  
Figure 1. Though 52% of neonates treated with phenobarbital had 
recurrent seizures while only 26% of neonates treated with 
fosphenytoin had recurrent  seizures, this was not statistically 
significant. There was also no statistical significance between both 
drugs in the need for a second anti-epileptic drug (AED) or if the 
neonate was discharged home on an AED. 
Comparative effectiveness of Fosphenytoin 
and phenobarbital 
Clinical Characteristics for First line Anti-
Epileptic Drugs 
Figures/Graphs 
Outcome Variables for First line Anti-Epileptic 
Drugs 
Table 1. Infants in both groups had similar baseline characteristics for 
neonatal variables as well as maternal antenatal complications 
18 Month Neurological Outcome 
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• Fosphenytoin as well as phenobarbital are equally 
efficacious as first-line AED in neonatal seizure 
control but neonates treated with fosphenytoin have 
significantly better neurodevelopmental outcomes at 
18 months of age.  
 
• Further multicenter studies are recommended to 
confirm our findings.   
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